Beta Bionics develops the iLet Bionic Pancreas, an automated insulin delivery system for people with diabetes. The company focuses on simplifying diabetes management with technology that helps automate insulin dosing.
UpMarket does not offer Beta Bionics shares. This page covers Beta Bionics's history before it went public.
Latest Price
$966.2M
IPO, Jan 2025, Perplexity
UpMarket Estimate
$1.0B
Based on UpMarket valuation model
Previous Price
$204M
IPO Jan 2025
How to Review Beta Bionics's Pre-IPO History on UpMarket
Beta Bionics became a public company on January 30, 2025 and trades on Nasdaq as BBNX. UpMarket does not offer Beta Bionics shares. This page covers Beta Bionics's valuation and funding history before it went public.
Step 01
Check the listing details
Beta Bionics listed on Nasdaq under the ticker BBNX on January 30, 2025.
Step 02
Review the valuation history
See how Beta Bionics's private-market valuation changed across funding rounds before it went public.
Step 03
Review funding and revenue data
See reported funding rounds and revenue figures on this page, with their sources.
Step 04
Explore private companies
Accredited investors can review UpMarket's current pre-IPO offerings in companies that have not yet gone public.
Pre-IPO investments are illiquid, speculative, and involve risk of total loss of capital.
${{aum_amount_brokered_en}}B+
UpMarket has brokered over ${{aum_amount_brokered_en}} billion in alternative investments*
*Includes principal invested and appreciation of investments originated via the UpMarket platform based on historical trade volume and valuation estimates through {{aum_as_of_date_en}}. Of the total, approximately ${{aum_amount_managed_en}} million is managed by UpMarket Management, with the remaining originated investments managed by affiliates. Past performance is not predictive of future results.
Valuation Growth Over Time
Post-money valuation by round
Previous roundsMost recent
Date
Round
PPS (split-adj.)
Valuation
Jan 2025
IPO
$966.2M
Jan 2025
IPO
$204M
Beta Bionics Revenue and Growth
Annual revenue
Why Investors Are Watching Beta Bionics
Market Opportunity
Beta Bionics raised $204M in upsized IPO for iLet growth
Beta Bionics priced an upsized initial public offering at $204 million, including a concurrent private placement to an existing investor. The company’s Nasdaq listing in January 2025 gave it public-market access to fund commercialization of the iLet Bionic Pancreas.
Beta Bionics is the maker of the iLet Bionic Pancreas, an automated insulin delivery device for people with type 1 diabetes. The company was founded in 2015 around the goal of making diabetes care more manageable with a bionic pancreas system.
Risk Factor
Beta Bionics is now publicly traded
Beta Bionics became a public company on January 30, 2025 and trades on Nasdaq as BBNX. Its share price is set on the public market and can change significantly. UpMarket does not offer Beta Bionics shares.
Looking for companies that are still private? Browse UpMarket's pre-IPO company directory. Accredited investors only.
UpMarket curates and conducts independent diligence on every investment opportunity before it reaches the platform.
Strategy, fees & legal reviewed in full
We review every offering's strategy, risk management, liquidity, fees, valuation methodology, tax matters, and all third-party providers: legal counsel, auditor, administrator, and custodian.
Disciplined managers only
We offer investments exclusively from disciplined managers that pursue unique strategies across an array of asset classes.
Built around your objectives
Our goal is to empower you to build a portfolio that best meets your individual investment objectives.
Yes. Beta Bionics became a public company on January 30, 2025 and trades on Nasdaq under the ticker BBNX. UpMarket does not offer Beta Bionics shares.
Beta Bionics's share price is set on the public market under the ticker BBNX. The prices shown on this page are historical private-market prices from before it went public.
No. Beta Bionics is now a public company and UpMarket does not offer its shares. Accredited investors interested in companies that have not yet gone public can review UpMarket's current pre-IPO offerings.
Beta Bionics is now publicly traded, so its shares can be bought and sold on Nasdaq and their price can change significantly. Review Beta Bionics's public filings and consult a financial advisor before investing. UpMarket does not offer Beta Bionics shares.
In a pre-IPO transaction, accredited investors purchase shares from existing shareholders (such as employees, early investors, or other holders) through secondary market platforms. The company itself does not issue new shares in these transactions. UpMarket facilitates these trades as a FINRA-registered broker-dealer, handling compliance, documentation, and settlement on behalf of both parties.
Beta Bionics became a public company on January 30, 2025, so shares held before the listing can generally be sold on the public market once any lock-up period ends. The exact terms depend on how the shares are held, for example directly or through a fund.
UpMarket does not offer Beta Bionics shares. The minimum for most pre-IPO offerings on UpMarket is $50,000.
Beta Bionics's valuation is now set by its public share price on Nasdaq. The figures on this page show its valuation history before it went public.
Beta Bionics develops the iLet Bionic Pancreas for automated insulin delivery in diabetes care and reported $27.6M in Q1 2026 revenue, following its $204M upsized IPO to fund iLet growth. Beta Bionics is now a public company, and UpMarket does not offer its shares.